TRACY COE: Open Payments
NPI 1275568602 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,447 in 89 payments from 14 companies in 2025. Trend: 2023 $1,849 · 2024 $1,860 · 2025 $2,447
Food & beverage: $2,447
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $678 |
| Regeneron Healthcare Solutions, Inc. | 20 | $407 |
| GENZYME CORPORATION | 5 | $300 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $187 |
| GlaxoSmithKline, LLC. | 14 | $161 |
| Blueprint Medicines Corporation | 2 | $159 |
| Grifols USA, LLC | 7 | $142 |
| Novartis Pharmaceuticals Corporation | 5 | $127 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $108 |
| Optinose US, Inc. | 3 | $66 |
Products named: DUPIXENT, TEZSPIRE, CUVITRU, AYVAKIT, FASENRA, Xembify, Xolair, NEFFY.
Industry payments across TX — which companies pay providers there.
